ArticleEndocrinology2025
Mechanisms in Thyroid Eye Disease: The TSH Receptor Interacts Directly With the IGF-1 Receptor.
Article in Endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- A bispecific-aptamer TSHR-CD80-1 treats thyroid eye disease by inhibiting CD8Cell communication and signaling : CCS · 2026Article
- What has changed in thyroid eye disease in the last five years (2020-2025).European thyroid journal · 2026Review
- Article
- Unravelling the pathogenic mechanisms in Graves' orbitopathy.European thyroid journal · 2025Review
- Mechanisms in Thyroid Eye Disease: The TSH Receptor Interacts Directly With the IGF-1 Receptor.Endocrinology · 2025Article
- Emerging therapeutic approaches in graves' ophthalmopathy: an update on pharmacological interventions.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The pathogenesis of thyroid eye disease (TED) has been suggested as due to signal enhancement in orbital fibroblasts as a result of autoantibody-induced, synergistic interaction between the TSH receptor (TSHR) and the IGF-1 receptor (IGF-1R). This interaction has been explained by a "receptor cross-talk," mediated via β-arrestin binding. Here we have examined if this interaction can be mediated via direct receptor contact using modeling and experimental approaches. First, we docked a model of the leucine-rich domain of the TSHR ectodomain (ECD) to an available cryo-electron microscopy-based structure of the active-state IGF-1R dimer and demonstrated the stability of the complex using molecular dynamics simulations. We then extended the complex with the full-length TSHR and the transmembrane helices of the IGF1R and a 3000 ns simulation also showed stability of this complex. We then performed coimmunoprecipitation studies with anti-TSHR and anti-IGF-1R antibodies using cells expressing the IGF-1R and the full-length TSHR and also cells that expressed the IGF-1R and only the TSHR-ECD and, therefore, unable to bind β-arrestin. These studies showed a 360 kD complex protein in the immunoprecipitation, which was present in both the full-length TSHR and the TSHR-ECD-only expressing cells, evidencing a direct interaction of receptors via their ectodomains in the absence of arrestin. Colocalized staining of TSHR and IGF-1R in the TSHR-ECD cells further supported this direct interaction. These data showed that the TSHR and IGF-1R can interact directly and in the absence of β-arrestin binding. Understanding these interactions is important in the pathogenesis of TED and its therapeutic intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.